直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

Authored and Edited by Forrest A. Jones; Umber Aggarwal; Candace C. Walther

In Freightcar America, Inc. v. National Steel Car Limited, IPR2025-01047, Director Squires de-instituted an already-instituted IPR after a patent owner filed its patent owner response. The decision rested on the patent owner’s post-institution disclaimer of the claims that formed the basis for institution.

The Board’s institution decision found a reasonable likelihood of unpatentability for claim 24, but not for the remaining challenged claims. Following institution, patent owner disclaimed claim 24 and its dependents and requested Director Review of the decision granting institution of the IPR, arguing that it had disclaimed the claims for which the Board found a reasonable likelihood of unpatentability. Petitioner argued that Director Review is improper when it relies on new evidence—such as a post-institution disclaimer—rather than identifying any error in the Board’s institution decision.

The Director granted review, vacated the decision granting institution, and denied institution. The Director explained that the disclaimed claims “are treated as though they never existed,” citing Federal Circuit precedent. Because the Board had already determined that the petitioner failed to show a reasonable likelihood of success as to any remaining, non-disclaimed claims, the Director found that “maintaining this IPR is an inefficient use of Office resources.”

This decision highlights a strategic path for patent owners to use a targeted disclaimer strategy, coupled with Director Review, to overcome institution of IPR proceedings where institution hinges on only a subset of claims. However, this avenue would seem to only be available if the Office issues a decision explaining its reasons for institution, which, under the current procedure, the Office usually will not. This decision also demonstrates that Director Review of institution remains available even once the IPR is at an advanced stage.

Tags

Patent Trial and Appeal Board (PTAB)

Related Practices

Global IP Enforcement, Litigation, and Trials

Patent Litigation and Trials

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Chemicals, Industrials, and Materials

Manufacturing

Transportation and Logistics

Related Offices

Washington, DC

Contacts

Forrest A. Jones
Partner
Washington, DC
+1 202 408 4019
Email
Umber Aggarwal
Associate
Reston, VA
+1 571 203 2423
Email
Candace C. Walther
Associate
Atlanta, GA
+1 404 653 6478
Email

Copyright © 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP